triazolam has been researched along with Sleep Apnea, Central in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
Sleep Apnea, Central: A condition associated with multiple episodes of sleep apnea which are distinguished from obstructive sleep apnea (SLEEP APNEA, OBSTRUCTIVE) by the complete cessation of efforts to breathe. This disorder is associated with dysfunction of central nervous system centers that regulate respiration.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rocha, A | 1 |
| Pinto, ACPN | 1 |
| Pachito, DV | 1 |
| Drager, LF | 1 |
| Lorenzi-Filho, G | 1 |
| Atallah, ÁN | 1 |
1 review available for triazolam and Sleep Apnea, Central
| Article | Year |
|---|---|
Pharmacological treatment for central sleep apnoea in adults.
Topics: Acetazolamide; Adult; Aged; Apnea; Buspirone; Carbonic Anhydrase Inhibitors; Disorders of Excessive | 2023 |